However, based on the results published on the peak number of circulating CD34+ cells and apheresis yields, most of the patients could not be considered as hard-to-mobilize as pre-plerixafor median PB CD34+ counts were 33 × 106/L in NHL patients and 150 × 106/L in MM patients, respectively. The gene discussed is CD34; the disease is Miyoshi myopathy.